Expertise in

conditions

Dr. Mehmet Copur

Oncology

Thoracic Surgery Clinic At Mary Lanning Healthcare (Grand Island)

3563 Prairieview St Ste 100,

Grand Island, NE

Clinical Trials:Currently Recruiting for 4 Trials

44 Years of Experience

Expertise in

conditions

Thoracic Surgery Clinic At Mary Lanning Healthcare (Grand Island)

3563 Prairieview St Ste 100,

Grand Island, NE

Overview

Mehmet Copur is an Oncologist in Grand Island, Nebraska. Dr. Copur has been practicing medicine for over 44 years is highly rated in 74 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Breast Cancer, Lynch Syndrome, Bone Marrow Aspiration, and Pancreatectomy.

His clinical research consists of co-authoring 75 peer reviewed articles and participating in 102 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year

1982

Specialties

Oncology

Licenses

Internal Medicine in NE

Hospital Affiliations

York General Health Care Services

Howard County Medical Center

Thayer County Health Services

Mary Lanning Healthcare

Grand Island Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem BCBS

Blue Cross Blue Shield

Change Healthcare

OTHER MEDICARE
OTHER MEDICARE PART D

Cigna

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Humana

HMO
INDEMNITY
POS
PPO

Medica

Northern Plains Alliance

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE PDP

Oscar

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 7 Less Insurance Carriers -

Locations

Thoracic Surgery Clinic at Mary Lanning Healthcare (Grand Island)
3563 Prairieview St Ste 100, Grand Island, NE 68803

Call: 308-384-2446

Other Locations

St. Francis Medical Plaza
2116 W Faidley Ave, Grand Island, NE 68803

Call: 308-398-5450

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

102 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing

Enrollment Status: Recruiting

Publish Date: January 26, 2026

Intervention Type: Drug, Other, Radiation

Study Drug: Cisplatin

Study Phase: Phase 2

Integrated Cancer Repository for Cancer Research

Enrollment Status: Recruiting

Publish Date: January 22, 2026

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

Enrollment Status: Recruiting

Publish Date: January 12, 2026

Intervention Type: Drug

Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib

Study Phase: Phase 2

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Enrollment Status: Recruiting

Publish Date: December 22, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate

Study Phase: Phase 3

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Radiation, Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Biological, Procedure

Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate

Study Phase: Phase 2

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug

Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 2

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: February 11, 2026

Intervention Type: Drug

Study Drugs: Capecitabine, Carboplatin, Cisplatin

Study Phase: Phase 3

S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification

Enrollment Status: Completed

Publish Date: February 10, 2026

Intervention Type: Device, Biological, Other, Drug

Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab

Study Phase: Phase 2

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 10, 2026

Intervention Type: Drug, Other

Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate

Study Phase: Phase 3

A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: February 06, 2026

Intervention Type: Drug, Other, Biological

Study Drugs: Afatinib Dimaleate, Cetuximab

Study Phase: Phase 2/Phase 3

Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin

Enrollment Status: Completed

Publish Date: February 06, 2026

Intervention Type: Other, Biological, Radiation

Study Drugs: Cetuximab, Durvalumab

Study Phase: Phase 2/Phase 3

JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: February 06, 2026

Intervention Type: Drug

Study Drugs: Abemaciclib, Erlotinib

Study Phase: Phase 3

The National Myelodysplastic Syndromes Natural History Study

Enrollment Status: Completed

Publish Date: February 03, 2026

Intervention Type: Other

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Enrollment Status: Active_not_recruiting

Publish Date: February 02, 2026

Intervention Type: Other, Procedure, Drug

Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 3

Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

Enrollment Status: Active_not_recruiting

Publish Date: January 29, 2026

Intervention Type: Drug

Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone

Study Phase: Phase 2

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Procedure

Study Phase: Phase 3

A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer

Enrollment Status: Completed

Publish Date: January 22, 2026

Intervention Type: Procedure

Study Phase: Phase 3

Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

Enrollment Status: Active_not_recruiting

Publish Date: January 22, 2026

Intervention Type: Drug, Radiation

Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine

Study Phase: Phase 3

Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study

Enrollment Status: Active_not_recruiting

Publish Date: January 22, 2026

Intervention Type: Drug

Study Drugs: Fulvestrant, Anastrozole

Study Phase: Phase 3

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

Enrollment Status: Completed

Publish Date: December 31, 2025

Intervention Type: Drug

Study Drugs: TAK-700, Bicalutamide

Study Phase: Phase 3

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)

Enrollment Status: Active_not_recruiting

Publish Date: December 30, 2025

Intervention Type: Other, Drug, Biological

Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel

Study Phase: Phase 3

Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Enrollment Status: Active_not_recruiting

Publish Date: December 29, 2025

Intervention Type: Drug, Other

Study Drugs: Capecitabine, Carboplatin, Cisplatin, Etoposide, Temozolomide

Study Phase: Phase 2

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Enrollment Status: Active_not_recruiting

Publish Date: December 19, 2025

Intervention Type: Other, Drug

Study Drug: Crizotinib

Study Phase: Phase 3

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: December 18, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate

Study Phase: Phase 3

A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With Trastuzumab in Stage I-II HER2/Neu Positive Breast Cancer Patients

Enrollment Status: Completed

Publish Date: December 12, 2025

Intervention Type: Drug, Biological, Other

Study Drugs: Cyclophosphamide, Paclitaxel, Trastuzumab

Study Phase: Phase 2

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Enrollment Status: Completed

Publish Date: December 04, 2025

Intervention Type: Drug, Radiation, Biological

Study Phase: Phase 2

A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Other, Drug

Study Drugs: Docetaxel, Trametinib

Study Phase: Phase 2

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride

Study Phase: Phase 2/Phase 3

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Other, Biological, Procedure

Study Drug: Nivolumab

Study Phase: Phase 3

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Radiation, Drug, Other

Study Drugs: Cisplatin, Triapine

Study Phase: Phase 3

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Drug, Procedure, Biological, Radiation

Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Drug, Other

Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib

Study Phase: Phase 2

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Drug, Procedure, Other

Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride

Study Phase: Phase 3

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Procedure, Drug, Other

Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride

Study Phase: Phase 2/Phase 3

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: November 28, 2025

Intervention Type: Drug, Biological, Other

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate

Study Phase: Phase 2

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Enrollment Status: Active_not_recruiting

Publish Date: November 28, 2025

Intervention Type: Other, Drug

Study Drugs: Temozolomide, Veliparib

Study Phase: Phase 2/Phase 3

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: November 25, 2025

Intervention Type: Drug, Other

Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy

Study Phase: Phase 3

Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

Enrollment Status: Active_not_recruiting

Publish Date: November 25, 2025

Intervention Type: Radiation, Drug

Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab

Study Phase: Phase 2

Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer

Enrollment Status: Terminated

Publish Date: November 20, 2025

Intervention Type: Radiation

Study Phase: Phase 2

A Phase II Study of Neoadjuvant Chemotherapy With and Without Trastuzumab in Patients With Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: November 18, 2025

Intervention Type: Drug, Radiation, Biological, Other, Procedure

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel, Trastuzumab

Study Phase: Phase 2

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Phase: Phase 3

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

Enrollment Status: Active_not_recruiting

Publish Date: November 14, 2025

Intervention Type: Procedure, Drug, Other

Study Drug: Pazopanib Hydrochloride

Study Phase: Phase 3

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

Enrollment Status: Completed

Publish Date: November 13, 2025

Intervention Type: Other, Drug

Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide

Study Phase: Phase 2/Phase 3

View 46 Less Clinical Trials

74 Total Publications

Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide With Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer.

Journal: Clinical breast cancer

Published: May 09, 2024

View All 74 Publications

Similar Doctors

Expertise in

conditions

Dr. George Bascom

Oncology

Expertise in

conditions

Dr. George Bascom

Oncology

Heartland Hematology & Oncology P.C.

412 W 42nd St,

Kearney, NE

(37.8 miles away)

308-865-2303

Languages Spoken:

English

George Bascom is an Oncologist in Kearney, Nebraska. Dr. Bascom is highly rated in 5 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Intraductal Papilloma.

Expertise in

conditions

Jami Kezeor, NP

Oncology

Expertise in

conditions

Jami Kezeor, NP

Oncology

Saint Francis Cancer Treatment Center

2620 W Faidley Ave,

Grand Island, NE

(23.0 miles away)

308-398-5450

Languages Spoken:

English

See accepted insurances

Jami Kezeor is an Oncologist in Grand Island, Nebraska. Dr. Kezeor is highly rated in 1 condition, according to our data. Her top areas of expertise are Marginal Zone Lymphoma (MZL), Pediatric Low-Grade Glioma (pLGG), Small Lymphocytic Lymphoma (SLL), and ALK-Positive Non-Small Cell Lung Cancer.

VIEW MORE Oncologists

Frequently Asked Questions about Dr. Mehmet Copur

How do I make an appointment with Dr. Mehmet Copur?

You can book an appointment with Dr. Mehmet Copur by calling their office at 308-384-2446. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mehmet Copur a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mehmet Copur is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mehmet Copur specialize in?

While Dr. Mehmet Copur is a Oncology, they have specific expertise in Colorectal Cancer, Breast Cancer, and Lynch Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Mehmet Copur participate in research or clinical trials?

Yes. Dr. Mehmet Copur has published 74 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Mehmet Copur's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mehmet Copur accept my insurance?

Dr. Mehmet Copur accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 308-384-2446 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Copur's expertise for a condition

ConditionClose